

# Friday 5 October

8:15am	<b>Welcome</b>	Clarendon Auditorium
	<b>Plenary</b>   Chairs: John Kelly & Michael Henderson	
8:30am	Epidemiological Trends in Melanoma   <b>David Whiteman</b>	
	<hr/>	
	<b>Melanocyte Biology</b>   Chair: Kiarash Khosrotehrani	Clarendon Auditorium
9:15am	Insights into melanocyte development   <b>David Erich Fisher</b>	
9:40am	Host pigmentation factors and genotype analysis of high risk melanoma patients   <b>Richard Sturm</b>	
10:00am	Dissection of melanocytic subpopulations   <b>Fumihito Noguchi</b>	
	<b>Human vs Machine: Artificial Intelligence in Melanoma Diagnosis</b>   Chair: Victoria Mar	Clarendon D&E
9:15am	Artificial intelligence - The new frontier in melanoma diagnosis   <b>Justin Ko</b>	
9:35am	Early diagnosis using telemedicine and technology   <b>Peter Soyer</b>	
9:55am	<b>Panel Discussion</b>	
	<hr/>	
10:15am	<b>Morning Tea</b>	Exhibition Area
	<hr/>	
	<b>Melanomagenesis</b>   Chair: Graham Mann	Clarendon Auditorium
11:00am	Germline predictors of melanoma development   <b>Nick Hayward</b>	
11:30am	Mechanisms of UV radiation-induced melanoma formation   <b>Graeme Walker</b>	
11:50am	Incidence of melanoma in commercial pilots in Australia   <b>Catherine M Olsen</b>	
12:00pm	Melanin pigment and melanoma heterogeneity   <b>Gamze K Abali</b>	
12:10pm	Origin of vascular progenitors driving melanoma angiogenesis in vivo   <b>Kiarash Khosrotehrani</b>	
	<b>Prevention and Diagnosis</b>   Chairs: Richard Scolyer & Amanda Oakley	Clarendon D&E
11:00am	Overdiagnosis in melanoma - how big is the problem?   <b>David Whiteman</b>	
11:30am	Biopsy - controversies and developments   <b>John Kelly</b>	
11:45am	Borderline Lesions: histological and management challenges   <b>Richard Scolyer</b>	
12:05pm	The truth about sun protection and Vitamin D   <b>Rachel Neale</b>	
12:25pm	<b>Discussion</b>	
	<hr/>	
12:30pm	<b>Lunch</b>   ANZMTG AGM held in Clarendon D&E	Exhibition Area
	<hr/>	
	<b>Plenary</b>   Chair: Mark Shackleton	Clarendon Auditorium
1:30pm	Melanoma: clues to therapeutic efficacy from disease pathogenesis   <b>David Erich Fisher</b>	Sponsored by
		
	<b>Melanoma Genomics</b>   Chairs: Nick Hayward & Stephen Wong	Clarendon Auditorium
2:15pm	Insights from the Australian Melanoma Genome Project   <b>Graham Mann</b>	
2:45pm	Patters of evolution found in lethal melanomas stratify patient survival   <b>Anthony Papenfuss</b>	
3:10pm	Immunogenomic and bioinformatic approaches to predict immunogenicity   <b>Nic Waddell</b>	
	<b>Management of Primary Cutaneous Disease</b>   Chairs: Jonathan Stretch & Alex Chamberlain	Clarendon D&E
2:15pm	Sentinel Node Biopsy when should it be done   <b>Mark Smithers</b>	
2:30pm	Sentinel Node Biopsy when it should not be done   <b>John Spillane</b>	
2:40pm	Management of the Positive Sentinel Node Biopsy   <b>David Gyorki</b>	
2:55pm	Challenges of special subtypes of melanoma - ALM, desmoplastic, neurotropic, extensive LM   <b>Michael Henderson</b>	
3:10pm	<b>Panel Discussion</b>	
	<hr/>	
3:30pm	<b>Afternoon Tea</b>	Exhibition Area
	<hr/>	

# Friday 5 October

	<b>Molecular Targets and Melanoma Biology</b>   Chair: Helen Rizos	Clarendon Auditorium
4:00pm	Small molecule inhibitors of melanoma: from fungal creams to microRNAs   <b>Peter Leedman</b>	
4:20pm	Less is more: subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors in vitro and in vivo   <b>Brian Gabrielli</b>	
4:35pm	Overcoming therapy induced reprogramming of metabolism in BRAF V600 melanoma   <b>Lorey Smith</b>	
4:45pm	Dynamic regulation of melanoma cell proliferation and therapy resistance   <b>Nikolas Haass</b>	
5:00pm	OGT-mediated cellular reprogramming drives MAPKi-induced drug resistance   <b>Helmut Schaider</b>	
	<b>Management of Loco-Regional Disease</b>   Chairs: Angela Hong & Michael Millward	Clarendon D&E
4:00pm	Loco-regional strategies for local recurrence and in transit metastasis   <b>Jonathan Zager</b>	
4:30pm	Approaches to extensive regional nodal involvement   <b>Andrew Spillane</b>	
4:45pm	Vanessa Estall - Is there any role for Radiotherapy for loco-regional recurrence   <b>Vanessa Estall</b>	
4:55pm	Systemic therapies for loco-regional metastases   <b>Alex Menzies</b>	
	<b>Core Dermoscopy</b>   Chairs: Cliff Rosendahl & Marius Rademaker	Clarendon A
4:00pm	An approach to dermoscopy in clinical practice   <b>Cliff Rosendahl</b>	
4:20pm	Dermoscopic diagnosis of melanoma   <b>Marius Rademaker</b>	
4:35pm	How to distinguish benign imitators of melanoma with dermoscopy   <b>Caterina Longo</b>	
4:50pm	Interactive Dermoscopy Quiz   <b>Yan Pan</b>	
5:15pm - 6:15pm	Welcome Function & Poster Session	Exhibition Area Sponsored by  <b>NOVARTIS</b>
5:30pm - 7:30pm	<b>Evening Course</b>   Course Leaders: Pascale Guitera, Caterina Longo A course on the role of confocal microscopy in melanoma diagnosis and management	Clarendon Auditorium Sponsored by  <b>Pierre Fabre</b>

# Saturday 6 October

## Consumer Breakfast

Clarendon A

*"Champions against melanoma: taking control of Australia's disease"*

- 8:00am Breakfast served  
8:30am Welcome and Introduction from **Michael Sukkar MP**  
8:35am Exercise during melanoma treatment | **Narelle Williams**  
8:45am Panel Discussion featuring: **Tom Elliott - panel moderator, Jay Allen, Jess Van Zeil, Cam Rose, Ken Sheldon**  
9:25am Wrap Up

- 
- 8:30am **Plenary** | Chair: Georgina Long  
Adjuvant systemic therapies for melanoma | **Grant McArthur**

Clarendon Auditorium  
Sponsored by



Bristol-Myers Squibb

- 
- 9:15am **Tumour Immunology** | Chair: Peter Hersey  
9:35am Is there a role for cancer vaccines in the treatment of melanoma? | **Riccardo Dolcetti**  
9:50am The power of natural born killers | **Jai Rautela**  
10:05am Putting sentinels to work: harnessing dendritic cells for cancer immunotherapy | **Meredith O'Keefe**  
Changing the tumor vasculature to regulate immune cell trafficking in melanoma | **Claudine Bonder**

Clarendon Auditorium  
Sponsored by



- 
- 9:15am **Brain and Leptomeningeal Metastases** | Chair: Victoria Atkinson  
9:40am Breakthroughs in systemic therapy for brain metastases | **Michael Davies**  
9:55am Radiotherapy advances for treating cerebral metastases | **David Kok**  
Panel Clinical Cases | **Kate Drummond, Michael Davies, David Kok, Gerald Fogarty**

Clarendon D&E

- 
- 9:15am **Systemic Therapy for Melanoma** | Chair: Mark Voskoboynik  
9:35am Your patient has metastatic disease. What are the options? | **Rachel Roberts-Thomson**  
9:50am Side-effects of cancer immunotherapy | **Mark Voskoboynik**  
10:00am Dermatological Issues with systemic therapy | **Pablo Fernandez-Penas**  
**Clinical Cases**

Clarendon A

- 
- 10:15am **Morning Tea**

Exhibition Area

- 
- Empowering Immune and Stromal Cells Against Melanoma** | Chair: Shahneen Sandhu  
10:45am Immunotherapy combinations - which and why | **Tara Mitchell**  
11:15am Cold to hot transformation with intratumoral therapy in melanoma | **Adil Daud**  
11:40am Lessons from CAR-T-cell therapy for GD2-positive melanomas | **Tessa Gargett**  
11:55am Mesenchymal cell subsets in melanoma metastases | **Rod Dunbar**  
12:15pm Biology and implications of immunotherapy toxicities | **Rosalie Stephens**

Clarendon Auditorium

- 
- Oligo-Metastatic Disease** | Chair: David Speakman  
10:45am Debate Topical and injectable therapies for cutaneous metastases | **Diona Damian**  
11:00am Debate Surgery is the optimal management for oligo metastatic disease | **Jonathan Zager**  
11:15am Debate Surgery has no role for oligo-metastatic disease | **Andrew Haydon**  
11:30am Debate Radiation for oligometastatic disease should be offered regardless! | **Rohan Nair**  
11:45am **Clinical Cases**

Clarendon D&E

- 
- Advanced Dermoscopy and Confocal Microscopy** | Chairs: Alex Chamberlain & Peter Soyer  
10:45am Dermoscopic Subtypes of benign naevi and their significance | **Peter Soyer**  
11:05am Long and short term sequential dermoscopy | **Amanda Oakley**  
11:25am Vascular clues and amelanotic melanoma with dermoscopy | **Pascale Guitera**  
11:45am Dermoscopy of Melanocytic lesions of Acral sites and the Nail Apparatus | **Alex Chamberlain**  
12:05pm When should I refer for confocal microscopy? | **Caterina Longo**

Clarendon A

# Saturday 6 October

12:30pm	<b>Lunch</b>	Exhibition Area
1:30pm	<b>Plenary</b>   Chair: Catronia McLean Predicting patient outcomes   <b>Richard Scolyer</b>	Clarendon Auditorium
2:15pm	<b>Melanoma Targeted Therapies - The Next Wave</b>   Chair: George Au-Yeung Where to next with targeted therapies?   <b>Georgina Long</b>	Clarendon Auditorium
2:45pm	The potential of CDK4 inhibition in anti-melanoma therapy   <b>Karen Shepperd</b>	
3:00pm	Targeting pro-survival BCL-2 proteins for the treatment of melanoma   <b>Marco Herold</b>	
3:15pm	Repurposing epigenetic drugs to prime for immunotherapy   <b>Nikola Bowden</b>	
2:15pm	<b>Supportive Care and Survivorship</b>   Chairs: Victoria Beedle & Michael Jefford Survivorship: issues for patients with melanoma and other cancers   <b>Michael Jefford</b>	Clarendon D&E
2:40pm	Living beyond melanoma: is the fear different when you face recurrence or progression?   <b>Haryana Dhillon</b>	
2:55pm	Post-treatment follow-up and investigations for high-risk melanoma   <b>Robyn Saw</b>	
3:10pm	Survivorship issues faced by patients with early stage melanoma   <b>Donna Milne</b>	
3:20pm	Not another one! - Monitoring for secondary primary melanomas   <b>Yan Pan</b>	
2:15pm	<b>The Approach to Primary Melanoma: What do I need to know?</b>   Chairs: Paul Fishburn & Morton Rawlin Interpreting the pathology report for optimal management   <b>Catronia McLean</b>	Clarendon A
2:30pm	Approaches to biopsy of suspicious lesions   <b>Victoria Mar</b>	
2:50pm	Update on excision margins and practical aspects of melanoma surgery   <b>Angela Webb</b>	
3:05pm	Advanced surgery - which flap and when to graft?   <b>Michael Weymouth</b>	
3:20pm	<b>Audience Questions and Panel Discussion</b>	
3:30pm	<b>Afternoon Tea</b>	Exhibition Area
4:00pm	<b>Melanoma Biomarkers</b>   Chair: Stephen Wong Biomarker-based prediction of melanoma outcomes in high-risk patients   <b>Helen Rizos</b>	Clarendon Auditorium
4:20pm	Liquid biopsy and imaging in the monitoring of therapy response   <b>Shahneen Sandhu</b>	
4:40pm	Uses and biology of circulating melanoma cells   <b>Mel Ziman</b>	
4:00pm	<b>Advances in Non-Melanoma Skin Cancers</b>   Chairs: Alvin Chong & Ben Brady Curing Merkel cell carcinoma: Progress and Challenges   <b>Shailender Bhatia</b>	Clarendon D&E
4:25pm	Immunotherapy for Recurrent or Metastatic Cutaneous SCC   <b>Danny Rischin</b>	
4:45pm	Hedgehog pathway inhibitors for BCC   <b>Pablo Fernandez-Penas</b>	
4:00pm	<b>Consumer Driven Initiatives</b>   Chairs: Tamara Dawson & Michael Henderson Ensuring the quality of melanoma care: The National Melanoma Guidelines - the consumer perspective   <b>Alison Button-Sloan</b>	Clarendon A
4:10pm	Ensuring the quality of melanoma care: The National Melanoma Guidelines - the clinician perspective   <b>John Thompson</b>	
4:25pm	What it feels like for an understudied group of survivors- the survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors and combination BRAF and MEK inhibitors   <b>Julia Lai-Kwon</b>	
4:35pm	Treatment toxicity vs treatment benefit - what is the right balance?   Consumer Panel Discussion moderated by <b>Grant McArthur</b>	
5:00pm	<b>The Australian Melanoma Clinical Outcomes Registry</b>   Chair: Mark Shackleton <b>Graham Mann</b>	Clarendon Auditorium
5:20pm	<b>Conference Close and Prizes</b>	Clarendon Auditorium